FILTRO SOLAR COM TETRASSULFONATO DE FENIL DIBENZIMIDAZOL DISSÓDICO E ÁCIDO TEREFTALILIDENO DICANFOR SULFÔNICO

A cosmetic formulation using triethanolamine salts of disodium phenyl dibenzimidazole tetrasulfonate and terephthalylidene dicamphor sulfonic acid addresses fluorescence issues in UV-A filters, improving their cosmetic application by reducing fluorescence and eliminating troxerutin reliance.

BR112025021047A2Pending Publication Date: 2026-11-10BEIERSDORF AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025021047
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-30
Filing Date
2024-03-15
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing UV-A filters, such as disodium phenyl dibenzimidazole tetrasulfonate, exhibit significant fluorescence under certain wavelengths, limiting their use in cosmetics, and combining them with troxerutin does not fully eliminate this issue while also posing compatibility and cost concerns.

Method used

A cosmetic preparation comprising the triethanolamine salts of disodium phenyl dibenzimidazole tetrasulfonate and terephthalylidene dicamphor sulfonic acid, formulated at specific concentrations and ratios, with an aqueous or aqueous-alcoholic gel base, and excluding certain ingredients, to reduce fluorescence.

Benefits of technology

Significantly reduces fluorescence of disodium phenyl dibenzimidazole tetrasulfonate, enhancing its usability in cosmetics without troxerutin, while maintaining effective UV protection.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to a cosmetic preparation containing a) the triethanolamine salt of disodium phenyl dibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate), b) the triethanolamine salt of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid).
Need to check novelty before this filing date? Find Prior Art

Description

1 / 11 Sunscreen with disodium phenyldibenzimidazole tetrasulfonate and teraphthalylidene dicaphor sulfonic acid. Description

[0001] The present invention relates to a cosmetic preparation comprising the triethanolamine salt of disodium phenyl dibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) and the triethanolamine salt of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid).

[0002] For many years, there has been an uninterrupted trend from aristocratic pallor to a healthy, athletic brown complexion. To achieve this, people expose their skin to solar radiation, as this causes the formation of pigments in the direction of melanin formation. However, ultraviolet radiation from sunlight also has a detrimental effect on the skin. In addition to acute damage (sunburns), long-term damage, such as an increased risk of developing skin cancer, occurs in the case of excessive irradiation with UVB light (wavelength: 280-320 nm). Excessive exposure to UVB and UVA radiation (wavelength: 320-400 nm) further leads to the weakening of elastic and collagen fibers in connective tissue. This leads to various phototoxic and photoallergic reactions, resulting in premature skin aging.

[0003] Therefore, to protect the skin, a range of photoprotective filter substances has been developed that can be used in cosmetic preparations. In most industrialized countries, these UVA and UVB filters are grouped together in the form of positive lists, such as Annex 7 of the Kosmetikverordnung [German Cosmetics Ordinance].

[0004] The multiplicity of commercially available sunscreens should not, however, distract from the fact that these prior art preparations have a range of disadvantages.

[0005] For many years, there has been a steadily increasing demand for UV-A filtering substances. This can be attributed, among other things, to the numerous government regulations requiring sunscreens to have a balanced ratio of UV-A and UV-B protection. However, the number of UV-A filters that Petition 870260112210, dated 10 / 30 / 2026, page 8 / 18 2 / 11 of the compounds that can be used in cosmetics is very limited. Essentially, oil-soluble compounds are used, such as butyl methoxydibenzoylmethane or diethylaminohydroxybenzoyl hexyl benzoate.

[0006] To obtain particularly high UV protection, however, it is necessary to also incorporate UV-A filters into the aqueous phase. For this purpose, around the turn of the millennium, Symrise developed the compound disodium phenyl dibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) as a water-soluble UVA filter. However, this substance has the disadvantage of fluorescing strongly in certain wavelength ranges. This effect was first observed by visitors in nightclubs that glowed in a bluish manner under “black light”. This fluorescence phenomenon initially rendered the UV filter unusable for further uses in cosmetics, and numerous research projects were launched to remedy the problem. Symrise found a promising first approach in the use of troxerutin. This solution was successfully patented under document EP2185126.

[0007] Although the combination with troxerutin led to a significant reduction in fluorescence, a weak residual fluorescence still remained, which further hampered the use of disodium phenyl dibenzimidazole tetrasulfonate in cosmetics. There are also reasons to avoid troxerutin in view of the costs of such a preparation and its compatibility (in individual cases allergic reactions cannot be ruled out).

[0008] Therefore, the objective of the present invention was to solve this problem of the prior art and to further reduce the fluorescence of disodium phenyl dibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) in cosmetic preparations without having to use troxerutin, or to reduce the amount of troxerutin used.

[0009] Surprisingly, the objective is achieved by a cosmetic preparation comprising a) the triethanolamine salt of disodium phenyl dibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate), Petition 870260112210, dated 10 / 30 / 2026, page 9 / 18 3 / 11 b) the triethanolamine salt of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid).

[0010] Those skilled in the art are familiar with document EP2185126. In addition, there is document DE 10 2022 203499.6, which has not yet been published at the time of this application, but these documents were unable to point the way to the present invention.

[0011] It is advantageous according to the invention if the preparation according to the invention comprises disodium phenyl dibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) at a concentration of 0.1% to 5% by weight, based on the total weight of the preparation. A content of 0.5% to 3% by weight, based on the total weight of the preparation, is preferred herein according to the invention.

[0012] This compound is neutralized with triethanolamine during the production of the preparation.

[0013] Furthermore, the embodiments of the present invention that are advantageous according to the invention are characterized in that the preparation comprises terephthalylidene Dicamphor Sulfonic Acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) at a concentration of 0.1% to 3% by weight, based on the total weight of the preparation. A content of 1% to 3% by weight, based on the total weight of the preparation, is preferred herein according to the invention.

[0014] This sulfonic acid is also neutralized with triethanolamine during the production of the preparation.

[0015] Additionally, it is advantageous in the context of the present invention if the weight ratio between disodium phenyl dibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) and terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) is from 0:3 to 1:1.

[0016] It is advantageous according to the invention if the preparation according to the invention is in the form of an aqueous or aqueous-alcoholic gel.

[0017] If the product is an aqueous gel, then the aqueous phase of neutralized disodium phenyl dibenzimidazole tetrasulfonate is incorporated into the neutralized aqueous phase of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid). Petition 870260112210, dated 10 / 30 / 2026, page 10 / 18 4 / 11 In other words: two aqueous subphases, each with one of the sulfonic acids, are prepared, neutralized separately with triethanolamine, and then combined to form an aqueous preparation.

[0018] The embodiments of the present invention that are advantageous according to the invention are characterized in that the preparation is free of 2-ethylhexyl 2-cyano-3,3-diphenylacrylate (Octocrylene), homomentyl salicylate (Homosalate), 2-ethylhexyl 4-methoxycinnamate, 3-(4-methylbenzylidene)camphor, 2-hydroxy-4-methoxybenzophenone (Oxybenzone), methyl anthranilate (INCI: Methyl Anthranilate) and sulisobenzone (INCI: Benzophenone-4).

[0019] Furthermore, it is advantageous according to the invention if the preparation according to the invention is free of polyethylene glycol, polyethylene glycol ethers and polyethylene glycol esters (referred to as PEG derivatives), is free of polyacrylates, mineral oils and silicone oils, and is free of parabens, methylisothiazolinone, chloromethylisothiazolinone and DMDM ​​hydantoin.

[0020] For the cosmetic preparation according to the invention or the process according to the invention, it is particularly advantageous according to the invention if the preparation comprises salts of 2-phenylbenzimidazole-5-sulfonic acid.

[0021] In such a case, the embodiments that are preferred according to the invention are characterized in that the preparation comprises 2-phenylbenzimidazole-5-sulfonic acid salts in a concentration of 0.1% to 8% by weight, based on the total weight of the preparation.

[0022] It is also advantageous according to the invention if the sodium salt or the triethanolamine salt is used as salts of 2-phenylbenzimidazole-5-sulfonic acid.

[0023] It is advantageous according to the invention if the preparation comprises one or more compounds selected from the group of xanthan gum (INCI: Xanthan Gum), welan gum (INCI: Welan Gum), gellan gum (INCI: Gellan Gum), sclerotium gum (INCI: Scerotium Gum), cellulose and / or cellulose derivatives. Advantageous celluloses and cellulose derivatives include, for example, microcrystalline cellulose, ethyl cellulose, propyl cellulose, hydroxypropyl cellulose, methoxyethyl cellulose, methoxypropyl cellulose and carboxymethyl cellulose. Petition 870260112210, dated 10 / 30 / 2026, page 11 / 18 BAD

[0024] Additionally, it is particularly advantageous according to the invention if the preparation according to the invention comprises ethylhexylglycerin and / or 4-hydroxyacetophenone.

[0025] If the preparation according to the invention comprises only ethylhexylglycerin and not 4-hydroxyacetophenone, then the concentration of use that is advantageous according to the invention is 0.1% to 0.5% by weight, based on the total weight of the preparation.

[0026] If the preparation according to the invention comprises only 4-hydroxyacetophenone and not ethylhexylglycerin, then the concentration of use that is advantageous according to the invention is 0.1% to 0.6% by weight, based on the total weight of the preparation.

[0027] If the preparation according to the invention comprises both ethylhexylglycerin and 4-hydroxyacetophenone, then the advantageous concentration of use according to the invention for ethylhexylglycerin is 0.1% to 0.5% by weight and for 4-hydroxyacetophenone is 0.1% to 0.6% by weight, in each case based on the total weight of the preparation.

[0028] Additionally, it is advantageous according to the invention if the preparation comprises silica and / or glass microspheres having a particle diameter of 5 to 120 µm.

[0029] Additionally, if the preparation according to the invention comprises a lipophilic phase, it is advantageous according to the invention if the preparation or process is characterized in that the preparation comprises hexyl 2-(4'-diethylamino-2'-hydroxybenzoyl)benzoate, 2,4,6-tris[anilino-(p-carbo-2'-ethyl-1'-hexyloxy)]-1,3,5-triazine (INCI: Ethylhexyl Triazone) and / or 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine).

[0030] In such a case, it is also advantageous according to the invention if the preparation or process is characterized in that the preparation comprises 2,4,6-tris(biphenyl-4-yl)1,3,5-triazine (INCI: Tris-Biphenyl Triazine), (2Z)-2-cyano-2-[3-(3-methoxypropylamino)cyclohex-2-en-1-ylidene]2-ethoxyethyl acetate (INCI: Methoxypropylamino Cyclohexenylidene Ethoxyethylcyanoacetate) and / or the compound Petition 870260112210, dated 10 / 30 / 2026, p. 12 / 18 6 / 11 Additionally, in such a case it is advantageous according to the invention if the preparation comprises lauryl glucoside and / or decyl glucoside.

[0001] The embodiments of the present invention that are advantageous according to the invention are characterized in that the preparation comprises one or more compounds selected from the following group of compounds: alpha-lipoic acid, folic acid, phytoene, D-biotin, coenzyme Q10, alpha-glucosylrutin, carnitine, carnosine, natural and / or synthetic isoflavonoids, flavonoids, creatine, creatinine, taurine, β-alanine, panthenol, magnolol, honokiol, tocopheryl acetate, dihydroxyacetone; 8-hexadecene-1,16-dicarboxylic acid, glyceryl glucose, (2-hydroxyethyl)urea, vitamin E and derivatives thereof, hyaluronic acid and / or salts thereof and / or licochalcone A.

[0002] It is advantageous according to the invention if the preparation comprises one or more alkanediols from the following group of compounds: pentane-1,2-diol, hexane-1,2-diol, octane-1,2-diol, decane-1,2-diol, 2-methylpropane-1,3-diol. The use of hexane-1,2-diol is preferred herein according to the invention.

[0003] It is also advantageous in the context of the present invention if the preparation according to the invention comprises one or more perfumes selected from the following group of compounds: limonene, citral, linalool, alpha-isomethyl ionone, geraniol, citronellol, 2-isobutyl-4-hydroxy-4-methyltetrahydropyran, 2-tert-pentylcyclohexyl acetate, 3-methyl-5-phenyl-1-pentanol, 7-acetyl-1,1,3,4,4,6-hexamethyltetraline, alpha-amyl cinnamaldehyde, alpha-methyl ionone, amyl C, butylphenyl methylpropional cinnamal, amyl salicylate, amyl cinnamyl alcohol, anise alcohol, benzoin, benzyl alcohol, benzyl benzoate, benzyl cinnamate, benzyl salicylate, bergamot oil, bitter orange oil, butylphenyl methylpropional, cardamom oil, cedrol, cinnamal, cinnamyl alcohol, citronellyl methylcrotonate, lime oil, coumarin, diethyl succinate, ethyl linalool, Petition 870260112210, dated 10 / 30 / 2026, page 13 / 18 7 / 11 eugenol, Evernia furfuracea extract, Evernia prunastri extract, farnesol, guaiac wood oil, hexyl cinnamal, hexyl salicylate, hydroxycitronellal, lavender oil, lemon oil, linalyl acetate, mandarin oil, menthyl PCA, methyl heptenone, nutmeg oil, rosemary oil, orange oil, terpineol, tonkao oil, triethyl citrate and / or vanillin.

[0004] According to the invention, the preparation according to the invention advantageously comprises film formers. In the context of the present invention, film formers are substances of varying composition characterized by the following property: if a film former is dissolved in water or other suitable solvents and the solution is then applied to the skin, after evaporation of the solvent, it forms a film that essentially serves to fix the light filters to the skin and thus increase the water resistance of the product.

[0005] These film formers may, for example, be selected from the group of polyvinylpyrrolidone (PVP)-based polymers or are polyvinylpyrrolidone copolymers, for example, PVP Hexadecene Copolymer and PVP Eicosene Copolymer, which are available under the trade names Antaron V216 and Antaron V220 from GAF Chemicals Corporation.

[0006] However, according to the invention, it is preferable if corn starch, maltodextrin and / or pullulan are used for this purpose.

[0007] Finally, and no less importantly, the preparations and processes according to the invention are characterized in that the preparation is free of troxerutin. Comparative experiment

[0008] The following formulations were produced and their fluorescence properties were investigated: Table 1 104 105 106 107 102 103 INCI EU Declaration % by weight % by weight % by weight % by weight % by weight % by weight Ethylhexylglycerin 0.20 0.20 0.20 0.20 0 0 Petition 870260112210, dated 10 / 30 / 2026, page 14 / 18 8 / 11 Hexane-1,2-diol 0.35 0.35 0.35 0.35 0 0 Water + Sodium Hydroxide 2.62 1.77 0 0 qs 0 Triethanolamine + Aqua 0 0 5.85 4.26 0 qs Phenoxyethanol + Aqua 0.80 0.80 0.80 0.80 0 0 Aqua 82.53 91.38 79.30 88.89 per 100 per 100 Water + Trisodium EDTA 0.50 0.50 0.50 0.50 0 0 8.00 0 8.00 0 Disodium Phenyl Dibenzimidazole Tetrasulfonate 2.00 2.00 2.00 2.00 3 3 Phenylbenz Imidazole Acid Sulfonic 3.00 3.00 3.00 3.00 0 0 Total: 100.00 100.00 100.00 100.00 100.00 100.00 Blue value at 365 nm 0.073±0.013 0.166±0.011 0.05±0.008 0.12±0.007 0.566±0.022 0.437±0.029 Blue value at 312 nm 0.076±0.013 0.185±0.008 0.06±0.006 0.145±0.01 0.547±0.021 0.357±0.03 Petition 870260112210, dated 10 / 30 / 2026, page 15 / 18 9 / 11 Fluorescence (color intensity at 365 and 312 nm) was determined as follows:

[0009] 3.0 ml of the samples are first transferred to glass Petri dishes (5 cm diameter). The Petri dishes are then placed individually on a dark surface. A commercially available DSLR or DSLM camera (here a Canon PowerShot SX540 HS) is mounted at a height of 30 cm. A UV lamp (here a 230V EU VL-6.LM 365 / 312 2x6W UV lamp; set to 365 or 312 nm) is mounted in the same way. The images in these examples were created with the following camera settings and are for guideline purposes only: ISO 400 document; F = 4.0; self-timer 25 s. The images are evaluated in a program that can separate them into color channels. GIMP 2.10.28 was used in this case. The color channels of the images can be separated into RGB colors using a histogram. The area of ​​the images being evaluated needs to be selected appropriately so that only the contents of the Petri dishes are separated in the histogram.The fluorescence value is determined based on the blue value at excitation wavelengths of 365 or 312 nm. Conclusion: Fluorescence and blue value are reduced by the presence of terephthalylidene dicamphor sulfonic acid and by the presence of triethanolamine. Examples

[0010] The following examples are intended to illustrate the present invention without limiting it. Unless otherwise indicated, all quantities, proportions and percentages are based on the weight and total quantity or total weight of the preparations. Table 2 Raw Material Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7 Sample 8 Sample 9 Sample 10 Disodium Phenyl Dibenzimidazole Tetrasulfonate 2 1 2 1 2 2 2 0 2 2 Petition 870260112210, dated 10 / 30 / 2026, page 16 / 18 10 / 11 Phenylbenzimidazole Sulfonic Acid 4 3 3 2 4 3 3 2 3 3 Terephthalylidene Dicamphor Sulfonic Acid 3 3 3 3 2.5 2.5 2 3 3 2.5 Glycerin 10 0 5 0 2 0 2 2 5 5 VP / Hexadecene Copolymer 0 0 0 0 0 0 0 0 0 0.5 Glyceryl Stearate 0 0 0 0 0 0 0 0 0 1 Triethanolamine 2.6 2.1 2.6 2.1 2.35 2.35 2.1 1.6 2.6 2.35 Sodium Hydroxide 0.6 0.45 0.45 0.3 0.6 0.45 0.45 0.3 0.45 0.45 Xanthan Gum 1 2 1 1 2 1 1 0.5 1 2 Ethylhexylglycerin 0.2 0.2 0.2 0 0.1 0.2 0.2 0.2 0.2 0.2 Trisodium EDTA 0.5 0.5 0.5 0.2 0.5 1 0.5 0.7 0.5 0.5 Phenoxyethanol 0.3 0.5 0.8 0 0.2 0.5 0.5 0.5 0.5 0.5 Hexane-1,2-diol 0.35 0.25 0.35 0 0.15 0.25 0.35 0.25 0.25 0.25 Ethanol 0 0 0 15 5 5 0 0 0 5 Pullulan 0 0 0 0 0.2 0 0 0 0.5 0 Polyglyceryl-10 Stearate 0 0 0 0 0 0 0 0 0 1 Tris-Biphenyl Triazine (and) Water (and) Decyl Glucoside (and) Butylene Glycol (and) Disodium Phosphate (and) Xanthan Gum 0 0 0 0 0 0 0 0 0 1 Petition 870260112210, dated 10 / 30 / 2026, page 17 / 18 11 / 11 Glass Microspheres 0 0 0 1 0 0 1 1 0 1 C12-15 Alkyl Benzoate 0 0 0 0 0 0 0 0 0 4 Ethylhexyl Triazone 0 0 0 0 0 0 0 0 0 2 Aqua Add to 100 Add to 100 Add to 100 Add to 100 Add to 100 Add to 100 Add to 100 Add to 100 Add to 100 Add to 100 Petition 870260112210, dated 10 / 30 / 2026, page 18 / 18

Claims

1 / 3 CLAIMS 1. Cosmetic preparation characterized by comprising a) the triethanolamine salt of disodium phenyl dibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate), b) the triethanolamine salt of terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid).

2. Cosmetic preparation, according to claim 1, characterized in that the preparation comprises disodium phenyl dibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) in a concentration of 0.1% to 5% by weight, based on the total weight of the preparation.

3. Cosmetic preparation, according to any of the preceding claims, characterized in that the preparation comprises terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) in a concentration of 0.1% to 3% by weight, based on the total weight of the preparation.

4. Cosmetic preparation, according to any of the preceding claims, characterized in that the weight ratio between disodium phenyl dibenzimidazole tetrasulfonate (INCI: Disodium Phenyl Dibenzimidazole Tetrasulfonate) and terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) is from 0:3 to 1:

1.

5. Cosmetic preparation, according to any of the preceding claims, characterized in that the preparation is in the form of an aqueous or aqueous-alcoholic gel.

6. Process for producing an aqueous cosmetic gel, as defined in any of the preceding claims, characterized in that terephthalylidene dicamphor sulfonic acid (INCI: Terephthalylidene Dicamphor Sulfonic Acid) is neutralized by means of triethanolamine in a first aqueous phase and then combined with a second aqueous phase separately produced in which disodium phenyl dibenzimidazole tetrasulfonate has been neutralized with triethanolamine.

7. Cosmetic preparation or process, according to any of the preceding claims, characterized in that the preparation is free of 2-ethylhexyl 2-cyano-3,3-diphenylacrylate (Octocrylene), homomentyl salicylate (Homosalate), 2-ethylhexyl 4-methoxycinnamate, 3-(4-methylbenzylidene)camphor, 2-hydroxy-4-methoxybenzophenone (Oxybenzone), methyl anthranilate (INCI: Methyl Anthranilate) and sulisobenzone (INCI: Benzophenone-4).

8. Cosmetic preparation or process, according to any of the preceding claims, characterized in that the preparation is free of polyethylene glycol, polyethylene glycol ethers and polyethylene glycol esters (referred to as PEG derivatives), is free of polyacrylates, mineral oils and silicone oils, and is free of parabens, methylisothiazolinone, chloromethylisothiazolinone and DMDM ​​hydantoin.

9. Cosmetic preparation or process, according to any of the preceding claims, characterized in that the preparation comprises salts of 2-phenylbenzimidazole-5-sulfonic acid.

10. Cosmetic preparation or process, according to claim 9, characterized in that the preparation comprises salts of 2-phenylbenzimidazole-5-sulfonic acid in a concentration of 0.1% to 8% by weight, based on the total weight of the preparation.

11. Cosmetic preparation or process, according to claim 10, characterized in that the sodium salt or triethanolamine salt is used as salts of 2-phenylbenzimidazole-5-sulfonic acid.

12. Cosmetic preparation or process, according to any of the preceding claims, characterized in that the preparation comprises one or more compounds selected from the group of xanthan gum (INCI: Xanthan Gum), welan gum (INCI: Welan Gum), gellan gum (INCI: Gellan Gum), sclerotium gum (INCI: Scerotium Gum), cellulose and / or cellulose derivatives.

13. Cosmetic preparation or process, according to any of the preceding claims, characterized in that the preparation comprises ethylhexylglycerin and / or 4-hydroxyacetophenone.

14. Cosmetic preparation or process, according to any of the preceding claims, characterized in that the preparation comprises silica and / or glass microspheres having a particle diameter of 5 to 120 µm.

15. Cosmetic preparation or process, according to any of the preceding claims, characterized in that the preparation comprises corn starch, maltodextrin and / or pullulan.

16. Cosmetic preparation or process, according to any of the preceding claims, characterized in that the preparation is free of troxerutin. Petition 870250088619, dated 09 / 30 / 2025, p. 24 / 63